Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working GroupPhilippe Moreau, Jean‐Luc Harousseau, Thomas G. Martin et al.|The Lancet Oncology|2021Cited by 266
Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)Sham Mailankody, Ola Landgren, Ruth M. Pfeiffer et al.|Blood|2011Cited by 198
The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple MyelomaElin Edda Sigurdardottir, Sigurður Y. Kristinsson, Ingemar Turesson et al.|JAMA Oncology|2015Cited by 145
Second malignancies after multiple myeloma: from 1960s to 2010sAnish Thomas, Ola Landgren, Sham Mailankody et al.|Blood|2012Cited by 127
Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple MyelomaOla Landgren, Ingemar Turesson, Jonathan N. Hofmann et al.|JAMA Oncology|2019Cited by 97